Abcam
Financials
Estimates*
GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 209m | 239m | 255m | 260m | 298m | 362m | 424m |
% growth | 21 % | 14 % | 7 % | 2 % | 15 % | 21 % | 17 % |
EBITDA | 67.9m | 90.3m | 70.7m | 66.4m | 43.8m | 42.7m | 137m |
% EBITDA margin | 33 % | 38 % | 28 % | 26 % | 15 % | 12 % | 32 % |
Profit | 40.7m | 63.6m | 44.1m | 12.5m | 14.6m | (8.5m) | 64.0m |
% profit margin | 20 % | 27 % | 17 % | 5 % | 5 % | (2 %) | 15 % |
EV / revenue | 9.1x | 11.0x | 11.5x | 10.8x | 9.1x | 7.4x | - |
EV / EBITDA | 27.9x | 29.2x | 41.5x | 42.1x | 61.5x | 62.5x | - |
R&D budget | 17.9m | 12.2m | 14.7m | 17.4m | 18.6m | 56.1m | - |
R&D % of revenue | 9 % | 5 % | 6 % | 7 % | 6 % | 16 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | N/A | IPO | |
N/A | $1.8m | - | |
N/A | $77.0m | Post IPO Equity | |
N/A | $180m | IPO | |
* | $5.7b Valuation: $5.7b 11.9x EV/LTM Revenues 101.1x EV/LTM EBITDA | Acquisition | |
Total Funding | €1.6m |
Recent News about Abcam
EditAbcam is a biotechnology company that specializes in the supply of antibodies and reagents, which are essential tools for scientific research and diagnostics. The company operates in the life sciences market, catering primarily to academic researchers, pharmaceutical companies, and diagnostic laboratories. Abcam's product range includes primary and secondary antibodies, biochemicals, cell and tissue imaging tools, and various kits and assays used in research areas such as cancer, cardiovascular diseases, cell biology, immunology, and neuroscience.
Abcam's business model is centered around providing high-quality, reliable products that help scientists achieve accurate and reproducible results in their experiments. The company offers a vast catalog of products, which can be easily searched and purchased through their website. Additionally, Abcam provides customized products and commercial partnerships to accelerate diagnostic and therapeutic programs, offering tailored solutions to meet specific research needs.
Revenue is generated through the direct sale of these products to researchers and institutions. The company also engages in partnerships and collaborations, which can include co-development agreements and licensing deals, further diversifying its income streams. Abcam's commitment to customer support and product quality has established it as a trusted supplier in the scientific community.
Keywords: antibodies, reagents, biotechnology, life sciences, diagnostics, research tools, customized products, partnerships, scientific research, pharmaceutical.